← All trials
NCT05831566
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Jan 31, 2025
- Completion date
- Jun 30, 2025
- First posted
- Apr 26, 2023
- Last posted
- Apr 26, 2023
- Enrollment
- 138
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Franciscus GasthuisLead sponsor
- Franciscus GasthuisReponsible party - principal investigator
- TevaCollaborator
- Franciscus GasthuisSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.